Hareth Nahi
11PUBLICATIONS
40CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (11)
Sort by Publication Date:
|Feb 14, 2025
Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes.Aurore Perrot, Thierry Facon, Torben Plesner
|Jan 15, 2025
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study.Philippe Moreau, Thierry Facon, Saad Z Usmani
|Mar 13, 2024
Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group.Anu Partanen, Anders Waage, Valdas Peceliunas
|Sep 06, 2022
Conditioning with melphalan 200 mg/m2 and subsequent ASCT improves progression-free and overall survival in elderly myeloma patients compared to standard of care.Gabriel Afram, Roza Chaireti, Katarina Uttervall
|Jan 02, 2022
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA.Thierry Facon, Gordon Cook, Saad Z Usmani
|Mar 22, 2021
Pyoderma gangrenosum with plasma cell dyscrasia should be subject for anti-myeloma treatment.Hareth Nahi, Gabriel Afram, Hanna Brauner
Pageof 2
Frequent Collaborators
2 joint publications
Katja Weisel
2 joint publications
Charlotte Gran
2 joint publications
Hartmut Goldschmidt
2 joint publications
Evren Alici
2 joint publications
Supratik Basu
2 joint publications
Saad Z Usmani
2 joint publications
Shaji Kumar
1 joint publications
Bertrand Arnulf
1 joint publications
Albert Oriol
1 joint publications
Jesus San-Miguel
